Current hormonal therapies for breast cancer, also known as antiestrogen therapies, usually target various types of ERs and selective ER modulators (SERMs) (27, 28) by default, for the treatment and prevention of breast cancers (29, 30), demonstrating the limitation of current endocrine therapy. The gene discussed is ESR1; the disease is breast carcinoma.